Helping cancer treatments succeed
in clinical trials
CellaraRx gives clinicians critical visibility into tumor biology, helping them enroll patients most likely to respond to cancer treatments in clinical trials - allowing effective drugs to demonstrate their true potential.
02
The Problem
Only 3.4% of cancer drugs reach FDA approval
Most cancer drugs fail in clinical trials - not because they don’t work, but because the wrong patients are enrolled.
Clinicians currently lack visibility into whether a patient’s tumor biology is a match for a drug before trial enrollment.
When biologically mismatched patients are included, true drug signals are diluted - and promising therapies are abandoned.
Cancer is difficult to treat because tumors are complex and unpredictable
Clinicians can see that cancer is present - but not which cells will resist treatment, or whether some cells are located in treatment resistant areas.
Without that visibility, it’s difficult to determine whether a patient’s tumor biology is truly a match for the drug being tested.
03
The Solution
What if drug trial enrollment wasn't blind?
CellaraRx reveals what
clinicians can’t see.
CellaraRx analyzes tumor biology at the single-cell level to predict whether a patient is likely to respond to a treatment - before a trial begins.
✔ Identifies treatment resistant cells and areas within tumor
✔ Maps where key cell types are located
✔ Predicts likelihood of patients response to treatment
04
Multitude of Benefits
Better trials.
Lower risk.
Stronger outcomes.
✔
For Drug Developers
✔ Better selection of patients in drug trials
✔ Fewer effective drugs fail in trials
✔ Faster development decisions
✔
For Pharma Investors
✔ De-risked drug development investments
✔ Capital deployed more efficiently
✔ Improved odds of FDA aproval beyond 3.4%
✔
For Cancer Patients
✔ Faster access to fully effective therapies
✔ Fewer failed cancer treatments
✔ More lives saved
05
Our Partners
